---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006945"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:35:22.645888+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital

## Summary
- Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.
- Cash and equivalents $1.0M at Sep 30; negative working capital of $0.2M.
- Post-year end: $1.5M from CEO-affiliated entity + $0.6M net from ATM offering.
- Pivoted EB05 (paridiprubart) to U.S. govt-funded ARDS study; plans EB06 IND submission.
- Topline Phase 2 EB06 results expected 12-18 months after FDA clearance; funded subject to capital.

## SEC filing metadata
- accession: 0001171843-24-006945
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184324006945/0001171843-24-006945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184324006945/f8k_121324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006945
- JSON: https://secwatch.observer/filing/0001171843-24-006945.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.